GlassScriptPhysician profile
Jill Generelli
NPI 1528532397
$4,315.20
in general payments reported to CMS, 2019-2025
31 companies · $540 in 2025
The $540 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $667 · 2022: $1,056 · 2023: $1,555 · 2024: $496 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,342 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,341.72 |
| Education | $250.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $783.10 | 2021-2023 | Breztri, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $755.81 | 2021-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $410.59 | 2023-2024 | Inspire |
| Jazz Pharmaceuticals INC. | $317.40 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $312.16 | 2021-2025 | Dupixent |
| Axsome Therapeutics, INC. | $231.55 | 2023 | Sunosi |
| Philips North America LLC | $200.21 | 2021-2024 | (Ak6) Vest Therapy |
| Harmony Biosciences LLC | $189.95 | 2022-2023 | Wakix |
| Genzyme Corporation | $167.90 | 2022-2025 | |
| Mylan Specialty L.P. | $129.32 | 2021-2024 | Yupelri |
| Novo Nordisk INC | $125.00 | 2022 | |
| Insmed, INC. | $122.09 | 2024-2025 | Arikayce, Brinsupri |
| Alkermes, INC. | $97.56 | 2023 | Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.05 | 2021-2023 | Ofev |
| Viatris Specialty LLC | $53.68 | 2025 | Yupelri |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $46.50 | 2021-2024 | |
| Baxter Healthcare | $43.72 | 2023 | Hillrom - Life 2000 Ventilation System |
| Teva Pharmaceuticals USA, INC. | $31.23 | 2021-2023 | Austedo Xr |
| Avadel Cns Pharmaceuticals, LLC | $29.17 | 2025 | Lumryz |
| Ethicon US, LLC | $26.09 | 2021 | |
| Verona Pharma, INC. | $23.89 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $17.28 | 2025 | Zepbound |
| Neurocrine Biosciences, INC. | $15.05 | 2023 | Ingrezza |
| Actelion Pharmaceuticals US, INC. | $14.97 | 2021 | |
| Mallinckrodt Hospital Products INC. | $14.78 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.05 | 2023 | Aralast |
| United Therapeutics Corporation | $13.98 | 2024 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $13.31 | 2023 | |
| Horizon Therapeutics Plc | $11.79 | 2022 | |
| Zoll Respicardia, INC. | $11.54 | 2022 | |
| Electromed, INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Generelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.